Axsome Therapeutics, Inc. (NASDAQ:AXSM) and Neurocrine Biosciences, Inc. (NASDAQ:NBIX) have returned -7% and 12% over the past six months, compared to a 21.25% return for the Insider Monkey Billionaire Index and 14% for the State Street SPDR S&P 500 ETF Trust. Axsome and Neurocrine are building their businesses around treatments for neurological and psychiatric conditions. Both have several opportunities to expand beyond their existing products, but they are at different stages of commercial development. Axsome is growing faster, while Neurocrine has a larger business, positive earnings, and a more established commercial operation. AXSM ranked 1st in our list of the 10 Best Under-the-Radar Stocks to Invest In.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.